Difference between revisions of "Marginal zone lymphoma"
m (Text replacement - "<span style="background:#00CD00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; border-style:solid;">Phase III</span>" to "style="background-color:#00CD00"|Phase III") |
m |
||
Line 28: | Line 28: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[http://bloodjournal.org/content/123/19/2944.long Flinn et al. 2014 (BRIGHT)] | + | |rowspan=2|[http://bloodjournal.org/content/123/19/2944.long Flinn et al. 2014 (BRIGHT)] |
− | |style="background-color:#00CD00"|Phase III | + | |rowspan=2 style="background-color:#00CD00"|Phase III |
− | |[[Marginal_zone_lymphoma#R-CHOP|R-CHOP]] | + | |[[Marginal_zone_lymphoma#R-CHOP|R-CHOP]] |
− | | | + | |style="background-color:#eeee00"|Seems not superior |
− | style="background | + | |- |
− | + | |[[Marginal_zone_lymphoma#R-CVP|R-CVP]] | |
− | + | |style="background-color:#eeee00"|Seems not superior | |
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 52: | Line 50: | ||
===References=== | ===References=== | ||
<!-- # Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] --> | <!-- # Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] --> | ||
− | # Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [ | + | # Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24591201 PubMed] |
==Chlorambucil (Leukeran) {{#subobject:10e826|Regimen=1}}== | ==Chlorambucil (Leukeran) {{#subobject:10e826|Regimen=1}}== | ||
Line 69: | Line 67: | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[Marginal_zone_lymphoma#Fludarabine_.28Fludara.29|Fludarabine]] | |[[Marginal_zone_lymphoma#Fludarabine_.28Fludara.29|Fludarabine]] | ||
− | | | + | |style="background-color:#ff0000"|Seems to have inferior OS |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 94: | Line 87: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)] | + | |rowspan=2|[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)] |
− | |style="background-color:#00CD00"|Phase III | + | |rowspan=2 style="background-color:#00CD00"|Phase III |
− | |[[Marginal_zone_lymphoma#Chlorambucil_.26_Rituximab|Chlorambucil & Rituximab]] | + | |[[Marginal_zone_lymphoma#Chlorambucil_.26_Rituximab|Chlorambucil & Rituximab]] |
− | | | + | |style="background-color:#ff0000"|Inferior EFS |
− | style="background | + | |- |
− | + | |[[#Rituximab_.28Rituxan.29|Rituximab]] | |
− | + | |style="background-color:#d3d3d3"|Not reported | |
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 114: | Line 105: | ||
===References=== | ===References=== | ||
<!-- Presented at the 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 15-18, 2011, and at the 53th Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011. --> | <!-- Presented at the 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 15-18, 2011, and at the 53th Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011. --> | ||
− | # Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. [http://jco.ascopubs.org/content/31/3/301.full link to original article] '''contains verified protocol''' [ | + | # Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. [http://jco.ascopubs.org/content/31/3/301.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23233721 PubMed] |
− | # Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [ | + | # Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295789 PubMed] |
## '''Abstract: Update:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] | ## '''Abstract: Update:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] | ||
Line 131: | Line 122: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)] | + | |rowspan=2|[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)] |
− | |style="background-color:#00CD00"|Phase III | + | |rowspan=2 style="background-color:#00CD00"|Phase III |
− | |[[Marginal_zone_lymphoma#Chlorambucil_.28Leukeran.29|Chlorambucil]] | + | |[[Marginal_zone_lymphoma#Chlorambucil_.28Leukeran.29|Chlorambucil]] |
− | | | + | |style="background-color:#00cd00"|Superior EFS |
− | style="background | + | |- |
− | + | |[[#Rituximab_.28Rituxan.29|Rituximab]] | |
− | + | |style="background-color:#d3d3d3"|Not reported | |
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 150: | Line 139: | ||
''Patients with stable disease or better proceeded to [[#Chlorambucil_.26_Rituximab_2|chlorambucil & rituximab consolidation]].'' | ''Patients with stable disease or better proceeded to [[#Chlorambucil_.26_Rituximab_2|chlorambucil & rituximab consolidation]].'' | ||
===References=== | ===References=== | ||
− | # Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [ | + | # Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295789 PubMed] |
# '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] | # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] | ||
Line 169: | Line 158: | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[Marginal_zone_lymphoma#Chlorambucil_.28Leukeran.29|Chlorambucil]] | |[[Marginal_zone_lymphoma#Chlorambucil_.28Leukeran.29|Chlorambucil]] | ||
− | | | + | |style="background-color:#00cd00"|Seems to have superior OS |
− | style="background | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 192: | Line 176: | ||
===References=== | ===References=== | ||
<!-- Presented at the 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 15-18, 2011, and at the 53th Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011. --> | <!-- Presented at the 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 15-18, 2011, and at the 53th Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011. --> | ||
− | # Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. [http://jco.ascopubs.org/content/31/3/301.full link to original article] '''contains verified protocol''' [ | + | # Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. [http://jco.ascopubs.org/content/31/3/301.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23233721 PubMed] |
==R-CHOP {{#subobject:f6aa15|Regimen=1}}== | ==R-CHOP {{#subobject:f6aa15|Regimen=1}}== | ||
Line 215: | Line 199: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[http://bloodjournal.org/content/123/19/2944.long Flinn et al. 2014 (BRIGHT)] | + | |rowspan=2|[http://bloodjournal.org/content/123/19/2944.long Flinn et al. 2014 (BRIGHT)] |
− | | | + | |rowspan=2 style="background-color:#eeee00"|Phase III, <20 in this arm |
− | style="background | + | |[[Marginal_zone_lymphoma#BR|BR]] |
− | + | |style="background-color:#eeee00"|Seems not superior | |
− | + | |- | |
− | + | |[[Marginal_zone_lymphoma#R-CVP|R-CVP]] | |
− | + | |style="background-color:#eeee00"|Seems not superior | |
− | |[[Marginal_zone_lymphoma#BR|BR]] | ||
− | | | ||
− | style="background | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 246: | Line 223: | ||
===References=== | ===References=== | ||
<!-- # Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] --> | <!-- # Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] --> | ||
− | # Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [ | + | # Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24591201 PubMed] |
==R-CVP {{#subobject:2ba05b|Regimen=1}}== | ==R-CVP {{#subobject:2ba05b|Regimen=1}}== | ||
Line 262: | Line 239: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[http://bloodjournal.org/content/123/19/2944.long Flinn et al. 2014 (BRIGHT)] | + | |rowspan=2|[http://bloodjournal.org/content/123/19/2944.long Flinn et al. 2014 (BRIGHT)] |
− | | | + | |rowspan=2 style="background-color:#eeee00"|Phase III, <20 in this arm |
− | style="background | + | |[[Marginal_zone_lymphoma#BR|BR]] |
− | + | |style="background-color:#eeee00"|Seems not superior | |
− | + | |- | |
− | + | |[[Marginal_zone_lymphoma#R-CHOP|R-CHOP]] | |
− | + | |style="background-color:#eeee00"|Seems not superior | |
− | |[[Marginal_zone_lymphoma#BR|BR]] | ||
− | | | ||
− | style="background | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 292: | Line 262: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] --> | <!-- # '''Abstract:''' Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] --> | ||
− | # Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [ | + | # Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24591201 PubMed] |
==Rituximab (Rituxan) {{#subobject:c82d07|Regimen=1}}== | ==Rituximab (Rituxan) {{#subobject:c82d07|Regimen=1}}== | ||
Line 305: | Line 275: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|'''Comparator''' | |'''Comparator''' | ||
+ | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
|[http://bloodjournal.hematologylibrary.org/content/102/8/2741.long Conconi et al. 2003 (IELSG 6)] | |[http://bloodjournal.hematologylibrary.org/content/102/8/2741.long Conconi et al. 2003 (IELSG 6)] | ||
|style="background-color:#EEEE00"|Phase II | |style="background-color:#EEEE00"|Phase II | ||
− | | | + | |style="background-color:#d3d3d3"| |
+ | |style="background-color:#d3d3d3"| | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/23/9/1979.long Martinelli et al. 2005] | |[http://jco.ascopubs.org/content/23/9/1979.long Martinelli et al. 2005] | ||
|style="background-color:#EEEE00"|Phase II | |style="background-color:#EEEE00"|Phase II | ||
− | | | + | |style="background-color:#d3d3d3"| |
+ | |style="background-color:#d3d3d3"| | ||
+ | |- | ||
+ | |rowspan=2|[http://www.ielsg.org/documents/ielsg19lug13.pdf Zucca et al. 2013 (IELSG-19)] | ||
+ | |rowspan=2 style="background-color:#00cd00"|Phase III | ||
+ | |[[#Chlorambucil_.28Leukeran.29|Chlorambucil]] | ||
+ | |style="background-color:#d3d3d3"|Not reported | ||
|- | |- | ||
− | |[ | + | |[[#Chlorambucil_.26_Rituximab|Chlorambucil & Rituximab]] |
− | | | + | |style="background-color:#d3d3d3"|Not reported |
− | style="background | ||
− | |||
− | |||
− | |||
− | |||
− | | | ||
|- | |- | ||
|[http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full Williams et al. 2016 (RESORT)] | |[http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full Williams et al. 2016 (RESORT)] | ||
|style="background-color:#EEEE00"|Non-randomized | |style="background-color:#EEEE00"|Non-randomized | ||
− | | | + | |style="background-color:#d3d3d3"| |
+ | |style="background-color:#d3d3d3"| | ||
|- | |- | ||
|} | |} | ||
Line 340: | Line 313: | ||
===References=== | ===References=== | ||
− | # Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. [http://bloodjournal.hematologylibrary.org/content/102/8/2741.long link to orginal article] '''contains verified protocol''' [ | + | # Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. [http://bloodjournal.hematologylibrary.org/content/102/8/2741.long link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12842999 PubMed] content property of [http://hemonc.org HemOnc.org] |
− | # Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. [http://jco.ascopubs.org/content/23/9/1979.long link to original article] '''contains verified protocol''' [ | + | # Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. [http://jco.ascopubs.org/content/23/9/1979.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15668468 PubMed] |
# '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] | # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] | ||
<!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. --> | <!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. --> | ||
− | # Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [ | + | # Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26970533 PubMed] |
=Untreated, non-randomized or retrospective data= | =Untreated, non-randomized or retrospective data= | ||
Line 375: | Line 348: | ||
===References=== | ===References=== | ||
− | # Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. [http://www.haematologica.org/content/94/5/738.long link to original article] '''contains verified protocol''' [ | + | # Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. [http://www.haematologica.org/content/94/5/738.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19336742 PubMed] |
==Cladribine (Leustatin) {{#subobject:b1fc89|Regimen=1}}== | ==Cladribine (Leustatin) {{#subobject:b1fc89|Regimen=1}}== | ||
Line 403: | Line 376: | ||
===References=== | ===References=== | ||
− | # Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Höfler G, Linkesch W, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002 Sep 15;20(18):3872-7. [http://jco.ascopubs.org/content/20/18/3872.long link to original article] '''contains verified protocol''' [ | + | # Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Höfler G, Linkesch W, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002 Sep 15;20(18):3872-7. [http://jco.ascopubs.org/content/20/18/3872.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12228207 PubMed] |
==Cladribine & Rituximab {{#subobject:3ac33|Regimen=1}}== | ==Cladribine & Rituximab {{#subobject:3ac33|Regimen=1}}== | ||
Line 432: | Line 405: | ||
===References=== | ===References=== | ||
− | # Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/2/264.long link to original article] '''contains verified protocol''' [ | + | # Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/2/264.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22983582 PubMed] |
==Doxycycline {{#subobject:342bb6|Regimen=1}}== | ==Doxycycline {{#subobject:342bb6|Regimen=1}}== | ||
Line 446: | Line 419: | ||
|- | |- | ||
|[http://jnci.oxfordjournals.org/content/98/19/1375.long Ferreri et al. 2006] | |[http://jnci.oxfordjournals.org/content/98/19/1375.long Ferreri et al. 2006] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients in this subgroup |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|[http://jco.ascopubs.org/content/30/24/2988.long Ferreri et al. 2012] | |[http://jco.ascopubs.org/content/30/24/2988.long Ferreri et al. 2012] | ||
Line 464: | Line 432: | ||
===References=== | ===References=== | ||
− | # Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. [http://jnci.oxfordjournals.org/content/98/19/1375.long link to original article] '''contains verified protocol''' [ | + | # Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. [http://jnci.oxfordjournals.org/content/98/19/1375.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17018784 PubMed] |
− | # Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012 Aug 20;30(24):2988-94. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903. [http://jco.ascopubs.org/content/30/24/2988.long link to original article] '''contains verified protocol''' [ | + | # Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012 Aug 20;30(24):2988-94. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903. [http://jco.ascopubs.org/content/30/24/2988.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22802315 PubMed] |
==Fludarabine & Rituximab {{#subobject:413f96|Regimen=1}}== | ==Fludarabine & Rituximab {{#subobject:413f96|Regimen=1}}== | ||
Line 497: | Line 465: | ||
===References=== | ===References=== | ||
− | # Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009 Nov 15;115(22):5210-7. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.24605/full link to orginal article] '''contains verified protocol''' [ | + | # Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009 Nov 15;115(22):5210-7. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.24605/full link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19672998 PubMed] |
==Ibritumomab tiuxetan (Zevalin) {{#subobject:cfb3aa|Regimen=1}}== | ==Ibritumomab tiuxetan (Zevalin) {{#subobject:cfb3aa|Regimen=1}}== | ||
Line 511: | Line 479: | ||
|- | |- | ||
|[http://onlinelibrary.wiley.com/doi/10.1111/bjh.13021/full Samaniego et al. 2014] | |[http://onlinelibrary.wiley.com/doi/10.1111/bjh.13021/full Samaniego et al. 2014] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients reported |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|[http://www.tandfonline.com/doi/full/10.3109/10428194.2014.975801 Lossos et al. 2014] | |[http://www.tandfonline.com/doi/full/10.3109/10428194.2014.975801 Lossos et al. 2014] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients reported |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 538: | Line 496: | ||
===References=== | ===References=== | ||
<!-- Study results were presented at 12th International Conference on Malignant Lymphoma Lugano, Switzerland, 2013. --> | <!-- Study results were presented at 12th International Conference on Malignant Lymphoma Lugano, Switzerland, 2013. --> | ||
− | # Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014 Oct;167(2):207-13. Epub 2014 Jul 8. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13021/full link to original article] '''contains verified protocol''' [ | + | # Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014 Oct;167(2):207-13. Epub 2014 Jul 8. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13021/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25040450 PubMed] |
− | # Lossos IS, Fabregas JC, Koru-Sengul T, Miao F, Goodman D, Serafini AN, Hosein PJ, Stefanovic A, Rosenblatt JD, Hoffman JE. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Leuk Lymphoma. 2015 Jun;56(6):1750-5. Epub 2014 Nov 20. [http://www.tandfonline.com/doi/full/10.3109/10428194.2014.975801 link to original article] [ | + | # Lossos IS, Fabregas JC, Koru-Sengul T, Miao F, Goodman D, Serafini AN, Hosein PJ, Stefanovic A, Rosenblatt JD, Hoffman JE. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Leuk Lymphoma. 2015 Jun;56(6):1750-5. Epub 2014 Nov 20. [http://www.tandfonline.com/doi/full/10.3109/10428194.2014.975801 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25315074 PubMed] |
==Lenalidomide (Revlimid) {{#subobject:4f6ca7|Regimen=1}}== | ==Lenalidomide (Revlimid) {{#subobject:4f6ca7|Regimen=1}}== | ||
Line 553: | Line 511: | ||
|- | |- | ||
|[http://www.haematologica.org/content/98/3/353.long Kiesewetter et al. 2012] | |[http://www.haematologica.org/content/98/3/353.long Kiesewetter et al. 2012] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients reported |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 570: | Line 523: | ||
===References=== | ===References=== | ||
− | # Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. [http://www.haematologica.org/content/98/3/353.long link to orginal article] '''contains verified protocol''' [ | + | # Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. [http://www.haematologica.org/content/98/3/353.long link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22899582 PubMed] |
==Lenalidomide & Rituximab {{#subobject:c8fa86|Regimen=1}}== | ==Lenalidomide & Rituximab {{#subobject:c8fa86|Regimen=1}}== | ||
Line 598: | Line 551: | ||
# '''Abstract:''' N. H. Fowler, P. McLaughlin, F. B. Hagemeister, L. W. Kwak, M. A. Fanale, S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, F. Samaniego. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 28:15s, 2010 (suppl; abstr 8036). 2010 ASCO Annual Meeting abstract 8036. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview==abst_detail_view&confID==74&abstractID==53803 link to abstract] | # '''Abstract:''' N. H. Fowler, P. McLaughlin, F. B. Hagemeister, L. W. Kwak, M. A. Fanale, S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, F. Samaniego. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 28:15s, 2010 (suppl; abstr 8036). 2010 ASCO Annual Meeting abstract 8036. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview==abst_detail_view&confID==74&abstractID==53803 link to abstract] | ||
# '''Abstract:''' Nathan H Fowler, MD, Sattva S. Neelapu, MD, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Robert Z. Orlowski, M.D., Ph.D., Michael Wang, M.D., Francesco Turturro, MD, Yasuhiro Oki, MD, Linda Catherine Lacerte, RN and Felipe Samaniego, MD, MPH. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. 2012 ASH Annual Meeting abstract 901. [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/901 link to abstract] --> | # '''Abstract:''' Nathan H Fowler, MD, Sattva S. Neelapu, MD, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Robert Z. Orlowski, M.D., Ph.D., Michael Wang, M.D., Francesco Turturro, MD, Yasuhiro Oki, MD, Linda Catherine Lacerte, RN and Felipe Samaniego, MD, MPH. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. 2012 ASH Annual Meeting abstract 901. [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/901 link to abstract] --> | ||
− | # Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. Epub 2014 Oct 15. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70455-3/fulltext link to original article] '''contains protocol''' [ | + | # Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. Epub 2014 Oct 15. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70455-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25439689 PubMed] |
==MCP {{#subobject:1cc3da|Regimen=1}}== | ==MCP {{#subobject:1cc3da|Regimen=1}}== | ||
Line 624: | Line 577: | ||
===References=== | ===References=== | ||
− | # '''Retrospective:''' Wöhrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Püspök A, Chott A, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003 Dec;14(12):1758-61. [http://annonc.oxfordjournals.org/content/14/12/1758.long link to orginal article] '''contains verified protocol''' [ | + | # '''Retrospective:''' Wöhrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Püspök A, Chott A, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003 Dec;14(12):1758-61. [http://annonc.oxfordjournals.org/content/14/12/1758.long link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14630681 PubMed] |
==PCR {{#subobject:6b1b68|Regimen=1}}== | ==PCR {{#subobject:6b1b68|Regimen=1}}== | ||
Line 639: | Line 592: | ||
|- | |- | ||
|[http://onlinelibrary.wiley.com/doi/10.1111/bjh.13367/full Samaniego et al. 2015] | |[http://onlinelibrary.wiley.com/doi/10.1111/bjh.13367/full Samaniego et al. 2015] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients in this subgroup |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 664: | Line 612: | ||
===References=== | ===References=== | ||
− | # Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun;169(6):814-23. Epub 2015 Mar 31. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13367/full link to original article] '''contains verified protocol''' [ | + | # Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun;169(6):814-23. Epub 2015 Mar 31. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13367/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25828695 PubMed] |
=Consolidation after upfront therapy= | =Consolidation after upfront therapy= | ||
Line 680: | Line 628: | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)] | |[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)] | ||
− | | | + | |style="background-color:#eeee00"|Non-randomized |
− | style="background:#eeee00 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 695: | Line 638: | ||
===References=== | ===References=== | ||
− | # Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [ | + | # Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295789 PubMed] |
==Chlorambucil & Rituximab {{#subobject:e72abc|Regimen=1}}== | ==Chlorambucil & Rituximab {{#subobject:e72abc|Regimen=1}}== | ||
Line 709: | Line 652: | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)] | |[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)] | ||
− | | | + | |style="background-color:#eeee00"|Non-randomized |
− | style="background:#eeee00 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 725: | Line 663: | ||
===References=== | ===References=== | ||
− | # Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [ | + | # Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295789 PubMed] |
==Rituximab (Rituxan) {{#subobject:1d6299|Regimen=1}}== | ==Rituximab (Rituxan) {{#subobject:1d6299|Regimen=1}}== | ||
Line 743: | Line 681: | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[#Rituximab_.28Rituxan.29_3|Salvage rituximab]] | |[[#Rituximab_.28Rituxan.29_3|Salvage rituximab]] | ||
− | | | + | |style="background-color:#00cd00"|Seems to have superior TTTF |
− | style="background:#00cd00 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 760: | Line 693: | ||
===References=== | ===References=== | ||
<!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. --> | <!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. --> | ||
− | # Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [ | + | # Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26970533 PubMed] |
=Relapsed/refractory, non-randomized or retrospective data= | =Relapsed/refractory, non-randomized or retrospective data= | ||
Line 776: | Line 709: | ||
|- | |- | ||
|[http://onlinelibrary.wiley.com/doi/10.1002/cncr.24714/full Kahl et al. 2010] | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.24714/full Kahl et al. 2010] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients reported |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 792: | Line 720: | ||
===References=== | ===References=== | ||
<!-- Preliminary research findings from this study were presented at the 2007 American Society of Hematology Annual Meeting and Exposition, Atlanta, Georgia, December 8-11, 2007. --> | <!-- Preliminary research findings from this study were presented at the 2007 American Society of Hematology Annual Meeting and Exposition, Atlanta, Georgia, December 8-11, 2007. --> | ||
− | # Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Jan 1;116(1):106-14. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.24714/full link to original article] '''contains verified protocol''' [ | + | # Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Jan 1;116(1):106-14. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.24714/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19890959 PubMed] |
==Bortezomib (Velcade) {{#subobject:448e81|Regimen=1}}== | ==Bortezomib (Velcade) {{#subobject:448e81|Regimen=1}}== | ||
Line 836: | Line 764: | ||
===References=== | ===References=== | ||
− | # Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. [http://www.haematologica.org/content/94/5/738.long link to original article] '''contains verified protocol''' [ | + | # Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. [http://www.haematologica.org/content/94/5/738.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19336742 PubMed] |
− | # Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group (IELSG). Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011 Mar;22(3):689-95. [http://annonc.oxfordjournals.org/content/22/3/689.long link to original article] '''contains verified protocol''' [ | + | # Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group (IELSG). Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011 Mar;22(3):689-95. [http://annonc.oxfordjournals.org/content/22/3/689.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20810546 PubMed] |
==BR {{#subobject:9b8c84|Regimen=1}}== | ==BR {{#subobject:9b8c84|Regimen=1}}== | ||
Line 852: | Line 780: | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/23/15/3383.long Rummel et al. 2005] | |[http://jco.ascopubs.org/content/23/15/3383.long Rummel et al. 2005] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients in this subgroup |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 871: | Line 794: | ||
===References=== | ===References=== | ||
− | # Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005 May 20;23(15):3383-9. [http://jco.ascopubs.org/content/23/15/3383.long link to original article] '''contains verified protocol''' [ | + | # Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005 May 20;23(15):3383-9. [http://jco.ascopubs.org/content/23/15/3383.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15908650 PubMed] |
==Cladribine & Rituximab {{#subobject:bedbe7|Regimen=1}}== | ==Cladribine & Rituximab {{#subobject:bedbe7|Regimen=1}}== | ||
Line 885: | Line 808: | ||
|- | |- | ||
|[http://www.haematologica.org/content/98/2/264.long Troch et al. 2012] | |[http://www.haematologica.org/content/98/2/264.long Troch et al. 2012] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients reported |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 905: | Line 823: | ||
===References=== | ===References=== | ||
− | # Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/2/264.long link to original article] '''contains verified protocol''' [ | + | # Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/2/264.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22983582 PubMed] |
==Clarithromycin (Biaxin) {{#subobject:bfabe7|Regimen=1}}== | ==Clarithromycin (Biaxin) {{#subobject:bfabe7|Regimen=1}}== | ||
Line 919: | Line 837: | ||
|- | |- | ||
|[http://annonc.oxfordjournals.org/content/26/8/1760.full Ferreri et al. 2015 (HD-K)] | |[http://annonc.oxfordjournals.org/content/26/8/1760.full Ferreri et al. 2015 (HD-K)] | ||
− | | | + | |style="background-color:#eeee00"|Phase II |
− | style="background:#eeee00 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 933: | Line 846: | ||
===References=== | ===References=== | ||
− | # Ferreri AJ, Sassone M, Kiesewetter B, Govi S, Scarfò L, Donadoni G, Raderer M. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015 Aug;26(8):1760-5. Epub 2015 May 1. [http://annonc.oxfordjournals.org/content/26/8/1760.full link to original article] '''contains verified protocol''' [ | + | # Ferreri AJ, Sassone M, Kiesewetter B, Govi S, Scarfò L, Donadoni G, Raderer M. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015 Aug;26(8):1760-5. Epub 2015 May 1. [http://annonc.oxfordjournals.org/content/26/8/1760.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25935794 PubMed] |
==Doxycycline {{#subobject:1a9a25|Regimen=1}}== | ==Doxycycline {{#subobject:1a9a25|Regimen=1}}== | ||
Line 947: | Line 860: | ||
|- | |- | ||
|[http://jnci.oxfordjournals.org/content/98/19/1375.long Ferreri et al. 2006] | |[http://jnci.oxfordjournals.org/content/98/19/1375.long Ferreri et al. 2006] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients in this subgroup |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 962: | Line 870: | ||
===References=== | ===References=== | ||
− | # Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. [http://jnci.oxfordjournals.org/content/98/19/1375.long link to original article] '''contains verified protocol''' [ | + | # Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. [http://jnci.oxfordjournals.org/content/98/19/1375.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17018784 PubMed] |
==Idelalisib (Zydelig) {{#subobject:1c0cad|Regimen=1}}== | ==Idelalisib (Zydelig) {{#subobject:1c0cad|Regimen=1}}== | ||
Line 977: | Line 885: | ||
|- | |- | ||
|[http://www.nejm.org/doi/full/10.1056/NEJMoa1314583 Gopal et al. 2014 (DELTA)] | |[http://www.nejm.org/doi/full/10.1056/NEJMoa1314583 Gopal et al. 2014 (DELTA)] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients in this subgroup |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 991: | Line 894: | ||
===References=== | ===References=== | ||
− | # Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. N Engl J Med. 2014 Jan 22. [http://www.nejm.org/doi/full/10.1056/NEJMoa1314583 link to original article] '''contains verified protocol''' [ | + | # Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. N Engl J Med. 2014 Jan 22. [http://www.nejm.org/doi/full/10.1056/NEJMoa1314583 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24450858 PubMed] |
## '''Update:''' '''Abstract:''' Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, PhD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD and Gilles Andre Salles, MD, PhD. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). ASH Annual Meeting 2014, Abstract 1708 [https://ash.confex.com/ash/2014/webprogram/Paper74940.html link to abstract] | ## '''Update:''' '''Abstract:''' Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, PhD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD and Gilles Andre Salles, MD, PhD. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). ASH Annual Meeting 2014, Abstract 1708 [https://ash.confex.com/ash/2014/webprogram/Paper74940.html link to abstract] | ||
Line 1,006: | Line 909: | ||
|- | |- | ||
|[http://www.haematologica.org/content/98/3/353.long Kiesewetter et al. 2012] | |[http://www.haematologica.org/content/98/3/353.long Kiesewetter et al. 2012] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 patients reported |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 1,023: | Line 921: | ||
===References=== | ===References=== | ||
− | # Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. [http://www.haematologica.org/content/98/3/353.long link to orginal article] '''contains verified protocol''' [ | + | # Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. [http://www.haematologica.org/content/98/3/353.long link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22899582 PubMed] |
==Rituximab (Rituxan) {{#subobject:29dc8b|Regimen=1}}== | ==Rituximab (Rituxan) {{#subobject:29dc8b|Regimen=1}}== | ||
Line 1,040: | Line 938: | ||
|[http://bloodjournal.hematologylibrary.org/content/102/8/2741.long Conconi et al. 2003] | |[http://bloodjournal.hematologylibrary.org/content/102/8/2741.long Conconi et al. 2003] | ||
|style="background-color:#EEEE00"|Phase II | |style="background-color:#EEEE00"|Phase II | ||
− | | | + | |style="background-color:#d3d3d3"| |
− | | | + | |style="background-color:#d3d3d3"| |
|- | |- | ||
|[http://jco.ascopubs.org/content/23/9/1979.long Martinelli et al. 2005] | |[http://jco.ascopubs.org/content/23/9/1979.long Martinelli et al. 2005] | ||
|style="background-color:#EEEE00"|Phase II | |style="background-color:#EEEE00"|Phase II | ||
− | | | + | |style="background-color:#d3d3d3"| |
− | | | + | |style="background-color:#d3d3d3"| |
|- | |- | ||
|[http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full Williams et al. 2016 (RESORT)] | |[http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full Williams et al. 2016 (RESORT)] | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[#Rituximab_.28Rituxan.29_2|Maintenance rituximab]] | |[[#Rituximab_.28Rituxan.29_2|Maintenance rituximab]] | ||
− | | | + | |style="background-color:#ff0000"|Seems to have inferior TTTF |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 1,067: | Line 960: | ||
===References=== | ===References=== | ||
− | # Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. [http://bloodjournal.hematologylibrary.org/content/102/8/2741.long link to orginal article] '''contains protocol''' [ | + | # Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. [http://bloodjournal.hematologylibrary.org/content/102/8/2741.long link to orginal article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12842999 PubMed] |
− | # Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. [http://jco.ascopubs.org/content/23/9/1979.long link to original article] '''contains protocol''' [ | + | # Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. [http://jco.ascopubs.org/content/23/9/1979.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15668468 PubMed] |
<!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. --> | <!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. --> | ||
− | # Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [ | + | # Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26970533 PubMed] |
==Vorinostat (Zolinza) {{#subobject:1d4752|Regimen=1}}== | ==Vorinostat (Zolinza) {{#subobject:1d4752|Regimen=1}}== | ||
Line 1,084: | Line 977: | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/29/9/1198.long Kirschbaum et al. 2011] | |[http://jco.ascopubs.org/content/29/9/1198.long Kirschbaum et al. 2011] | ||
− | | | + | |style="background-color:#ff0000"|Phase II, <20 pts in subgroup |
− | style="background:#ff0000 | ||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 1,098: | Line 986: | ||
===References=== | ===References=== | ||
− | # Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20;29(9):1198-203. Epub 2011 Feb 7. [http://jco.ascopubs.org/content/29/9/1198.long link to original article] '''contains verified protocol''' [ | + | # Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20;29(9):1198-203. Epub 2011 Feb 7. [http://jco.ascopubs.org/content/29/9/1198.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21300924 PubMed] |
=Response criteria= | =Response criteria= | ||
==NCI Sponsored International Working Group Criteria (1999)== | ==NCI Sponsored International Working Group Criteria (1999)== | ||
− | # Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. [http://jco.ascopubs.org/content/17/4/1244.long link to original article] [ | + | # Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. [http://jco.ascopubs.org/content/17/4/1244.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10561185 PubMed] |
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
[[Category:Malignant hematology regimens]] | [[Category:Malignant hematology regimens]] | ||
[[Category:Lymphoma regimens]] | [[Category:Lymphoma regimens]] |
Revision as of 17:54, 6 November 2016
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
21 regimens on this page
22 variants on this page
|
Untreated, randomized data
Note: Untreated in this context implies chemotherapy-naive. Some patients in the following studies, especially those with gastric MALT, received H. pylori eradication therapy or radiation prior to chemotherapy.
BR
back to top |
BR: Bendamustine, Rituximab
Regimen
Study | Evidence | Comparator | Efficacy |
Flinn et al. 2014 (BRIGHT) | Phase III | R-CHOP | Seems not superior |
R-CVP | Seems not superior |
Chemotherapy
Note: the bendamustine infusion instructions are for the Treanda formulation, which was discontinued on 3/31/2016.
- Bendamustine 90 mg/m2 IV over 30 minutes once on days 1 & 2
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Supportive medications
- Antiemetics, antipyretics, and antibiotics according to local standard of care
- Prophylactic use of G-CSF allowed according ASCO guidelines (2006)
28-day cycle for up to 8 cycles
References
- Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. link to original article contains verified protocol PubMed
Chlorambucil (Leukeran)
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Leblond et al. 2012 (WM1) | Phase III | Fludarabine | Seems to have inferior OS |
Chemotherapy
- Chlorambucil (Leukeran) 8 mg/m2 (6 mg/m2 per day if older than 75 years old) PO once per day on days 1 to 10
Supportive medications
- Recommended PCP prophylaxis with one of the following:
- Trimethoprim/Sulfamethoxazole (Bactrim SS) 1 tablet PO once per day
- Pentamidine (Nebupent) 300 mg inhaled once per month
28-day cycle for up to 12 cycles
Regimen #2
Study | Evidence | Comparator | Efficacy |
Zucca et al. 2013 (IELSG-19) | Phase III | Chlorambucil & Rituximab | Inferior EFS |
Rituximab | Not reported |
Chemotherapy
- Chlorambucil (Leukeran) 6 mg/m2 PO once per day on days 1 to 42
One course
Patients with stable disease or better proceeded to chlorambucil consolidation.
References
- Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. link to original article contains verified protocol PubMed
- Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains verified protocol PubMed
- Abstract: Update: E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). link to abstract
Chlorambucil & Rituximab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Zucca et al. 2013 (IELSG-19) | Phase III | Chlorambucil | Superior EFS |
Rituximab | Not reported |
Chemotherapy
- Chlorambucil (Leukeran) 6 mg/m2 PO once per day on days 1 to 42
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
One course
Patients with stable disease or better proceeded to chlorambucil & rituximab consolidation.
References
- Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains verified protocol PubMed
- Abstract: E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). link to abstract
Fludarabine (Fludara)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Leblond et al. 2012 (WM1) | Phase III | Chlorambucil | Seems to have superior OS |
Chemotherapy
- Fludarabine (Fludara) 40 mg/m2 (30 mg/m2 per day if older than 75 years old) PO once per day on days 1 to 5
Supportive medications
- Recommended PCP prophylaxis with one of the following:
- Trimethoprim/Sulfamethoxazole (Bactrim SS) 1 tablet PO once per day
- Pentamidine (Nebupent) 300 mg inhaled once per month
- Herpes zoster prophylaxis with one of the following:
- Valacyclovir (Valtrex) 500 mg PO once per day
- Acyclovir (Zovirax) 200 to 400 mg PO BID
28-day cycle for up to 6 cycles
References
- Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. link to original article contains verified protocol PubMed
R-CHOP
back to top |
R-CHOP: Rituximab, Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisone
Synonyms: R-CHOP-21, CHOP-R
Structured Concept: C9760 (NCI-T), C0393023 (NCI-MT/UMLS)
Example orders
Regimen
Study | Evidence | Comparator | Efficacy |
Flinn et al. 2014 (BRIGHT) | Phase III, <20 in this arm | BR | Seems not superior |
R-CVP | Seems not superior |
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg per cycle) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
Supportive medications
- Antiemetics, antipyretics, and antibiotics per local standard of care
- G-CSF "according to the American Society of Clinical Oncology guidelines"
21-day cycle for up to 8 cycles
References
- Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. link to original article contains verified protocol PubMed
R-CVP
back to top |
R-CVP: Rituximab, Cyclophosphamide, Vincristine, Prednisone
Regimen
Study | Evidence | Comparator | Efficacy |
Flinn et al. 2014 (BRIGHT) | Phase III, <20 in this arm | BR | Seems not superior |
R-CHOP | Seems not superior |
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 750 mg/m2 or 1000 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg per cycle) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
Supportive medications
- Antiemetics, antipyretics, and antibiotics per local standard of care
- G-CSF "according to the American Society of Clinical Oncology guidelines"
21-day cycle for up to 8 cycles
References
- Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. link to original article contains verified protocol PubMed
Rituximab (Rituxan)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Conconi et al. 2003 (IELSG 6) | Phase II | ||
Martinelli et al. 2005 | Phase II | ||
Zucca et al. 2013 (IELSG-19) | Phase III | Chlorambucil | Not reported |
Chlorambucil & Rituximab | Not reported | ||
Williams et al. 2016 (RESORT) | Non-randomized |
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once per week; initial infusion rate of 50 mg/H, then increased as tolerated by 50 mg/H every 30 minutes, to a maximum rate of 300 mg/H
Supportive medications
- Acetaminophen (Tylenol) 650 mg PO 30 minutes prior to each dose
- Diphenhydramine (Benadryl) 50 mg PO 30 minutes prior to each dose
4-week course
Patients with PR/CR in RESORT were randomized to indefinite rituximab versus salvage rituximab at time of progression.
References
- Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. link to orginal article contains verified protocol PubMed content property of HemOnc.org
- Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. link to original article contains verified protocol PubMed
- Abstract: E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). link to abstract
- Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. link to original article contains protocol PubMed
Untreated, non-randomized or retrospective data
Note: Untreated in this context implies chemotherapy-naive. Some patients in the following studies, especially those with gastric MALT, received H. pylori eradication therapy or radiation prior to chemotherapy.
Bortezomib (Velcade)
back to top |
Regimen
Study | Evidence |
Troch et al. 2009 | Phase II |
Chemotherapy
- Bortezomib (Velcade) 1.5 mg/m2 IV bolus once per day on days 1, 4, 8, 11
Supportive medications
- 5-HT3 antagonist IV immediately before Bortezomib (Velcade)
- 500 mL NS after Bortezomib (Velcade)
21-day cycle for up to 8 cycles
References
- Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. link to original article contains verified protocol PubMed
Cladribine (Leustatin)
back to top |
Regimen
Study | Evidence |
Jäger et al. 2002 | Phase II |
Chemotherapy
- Cladribine (Leustatin) 0.12 mg/kg IV over 2 hours once on days 1 to 5
Dose reductions:
- "In case of a persisting nadir of the WBCs = 4.0 × 10^9/L (or neutrophils = 1.5 × 10^9/L) and/or the platelets = 100 × 10^9/L, the next treatment cycle was delayed by 1 week until achieving normal values and then treatment was administered at a reduced dose of 0.1 mg/kg body weight."
Supportive medications
- Not described
28-day cycle for 4 to 6 cycles
References
- Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Höfler G, Linkesch W, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002 Sep 15;20(18):3872-7. link to original article contains verified protocol PubMed
Cladribine & Rituximab
back to top |
Regimen
Study | Evidence |
Troch et al. 2012 | Phase II |
Chemotherapy
- Cladribine (Leustatin) 0.1 mg/kg SC once per day on days 1 to 4
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO prior to Rituximab (Rituxan)
- Antihistamine IV prior to Rituximab (Rituxan)
- Either Ondansetron (Zofran) or Tropisetron (Navoban) IV immediately before Cladribine (Leustatin)
21-day cycle for up to 6 cycles
References
- Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. link to original article contains verified protocol PubMed
Doxycycline
back to top |
Regimen
Study | Evidence |
Ferreri et al. 2006 | Phase II, <20 patients in this subgroup |
Ferreri et al. 2012 | Phase II |
This treatment was intended for patients with ocular adnexal marginal zone lymphoma (OAMZL), given the association with Chlamydia psittaci.
Antibiotic therapy
- Doxycycline 100 mg PO BID
3-week course
References
- Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. link to original article contains verified protocol PubMed
- Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012 Aug 20;30(24):2988-94. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903. link to original article contains verified protocol PubMed
Fludarabine & Rituximab
back to top |
Regimen
Study | Evidence |
Salar et al. 2009 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV (or 40 mg/m2 PO) once per day on days 1 to 5
- Patients with gastric lymphoma received the cycle 1 dose intravenously to guarantee drug absorption
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Dose reductions:
- Patients >70 years old could receive Fludarabine (Fludara) at the above dose, but only once per day on days 1 to 3
Supportive medications
- Trimethoprim/Sulfamethoxazole prophylaxis (dose/schedule not listed) per physician preference
- No routine antiviral prophylaxis or G-CSF use
28-day cycles for 4-6 cycles
References
- Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009 Nov 15;115(22):5210-7. link to orginal article contains verified protocol PubMed
Ibritumomab tiuxetan (Zevalin)
back to top |
Regimen
Study | Evidence |
Samaniego et al. 2014 | Phase II, <20 patients reported |
Lossos et al. 2014 | Phase II, <20 patients reported |
Chemotherapy
- Rituximab (Rituxan) 250 mg/m2 IV once on day 1, then another single dose on day 8
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 14.8 MBq/kg (maximum dose of 1184 MBq) IV once on day 8, given after Rituximab (Rituxan)
Dose reductions:
- Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 11.1 MBq/kg (maximum dose of 1184 MBq) for platelet count between 100 and 149.
One course of therapy
References
- Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014 Oct;167(2):207-13. Epub 2014 Jul 8. link to original article contains verified protocol PubMed
- Lossos IS, Fabregas JC, Koru-Sengul T, Miao F, Goodman D, Serafini AN, Hosein PJ, Stefanovic A, Rosenblatt JD, Hoffman JE. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Leuk Lymphoma. 2015 Jun;56(6):1750-5. Epub 2014 Nov 20. link to original article PubMed
Lenalidomide (Revlimid)
back to top |
Regimen
Study | Evidence |
Kiesewetter et al. 2012 | Phase II, <20 patients reported |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Supportive medications
- Aspirin 100 mg PO once per day
28-day cycle for up to 6 cycles
References
- Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. link to orginal article contains verified protocol PubMed
Lenalidomide & Rituximab
back to top |
Regimen
Study | Evidence |
Fowler et al. 2014 | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) 20 mg PO once per day on days 1 to 21
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycles up to 12 cycles
References
- Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. Epub 2014 Oct 15. link to original article contains protocol PubMed
MCP
back to top |
MCP: Mitoxantrone, Chlorambucil, Prednisolone
Regimen
Study | Evidence |
Wöhrer et al. 2003 | Retrospective |
Chemotherapy
- Mitoxantrone (Novantrone) 8 mg/m2 IV once per day on days 1 & 2
- Chlorambucil (Leukeran) 3 mg/m2 PO TID (written in the reference as "3 x 3 mg/m2"; total dose per day is 9 mg/m2) on days 1 to 5
- Prednisolone (Millipred) 25 mg/m2 PO/IV once per day on days 1 to 5
28-day cycle for up to 8 cycles
References
- Retrospective: Wöhrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Püspök A, Chott A, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003 Dec;14(12):1758-61. link to orginal article contains verified protocol PubMed
PCR
back to top |
PCR: Pentostatin, Cyclophosphamide, Rituximab
Regimen
Study | Evidence |
Samaniego et al. 2015 | Phase II, <20 patients in this subgroup |
Chemotherapy
- Pentostatin (Nipent) 4 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Supportive medications
- Ondansetron (Zofran) 8 mg (route not specified) prior to chemo
- Diphenhydramine (Benadryl) 25 mg (route not specified) prior to chemo
- 500 ml of 5% dextrose/one-half normal saline before and after each pentostatin dose
- Filgrastim (Neupogen) at the discretion of the treating physician
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 15 of cycle 1
- Trimethoprim/Sulfamethoxazole (Bactrim DS) once per day three days per week during and for 1 month following therapy
- Acyclovir (Zovirax) 400 mg PO BID during and for 1 month following therapy
21-day cycle for 6 cycles
References
- Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun;169(6):814-23. Epub 2015 Mar 31. link to original article contains verified protocol PubMed
Consolidation after upfront therapy
Chlorambucil (Leukeran)
back to top |
Regimen
Study | Evidence |
Zucca et al. 2013 (IELSG-19) | Non-randomized |
Treatment preceded by chlorambucil induction.
Chemotherapy
- Chlorambucil (Leukeran) 6 mg/m2 PO once per day on days 1 to 14
28-day cycle for up to 4 cycles
References
- Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains verified protocol PubMed
Chlorambucil & Rituximab
back to top |
Regimen
Study | Evidence |
Zucca et al. 2013 (IELSG-19) | Non-randomized |
Treatment preceded by chlorambucil & rituximab induction.
Chemotherapy
- Chlorambucil (Leukeran) 6 mg/m2 PO once per day on days 1 to 14
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycle for up to 4 cycles
References
- Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains verified protocol PubMed
Rituximab (Rituxan)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Williams et al. 2016 (RESORT) | Phase III | Salvage rituximab | Seems to have superior TTTF |
Treatment preceded by rituximab.
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once every 13 weeks
Continued until treatment failure
References
- Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. link to original article contains protocol PubMed
Relapsed/refractory, non-randomized or retrospective data
Bendamustine
back to top |
Regimen
Study | Evidence |
Kahl et al. 2010 | Phase II, <20 patients reported |
Chemotherapy
Note: these infusion instructions are for the Treanda formulation, which was discontinued on 3/31/2016.
- Bendamustine 120 mg/m2 IV over 60 to 120 minutes once on days 1 & 2
21-day cycle for 6 to 8 cycles
References
- Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Jan 1;116(1):106-14. link to original article contains verified protocol PubMed
Bortezomib (Velcade)
back to top |
Regimen #1
Study | Evidence |
Conconi et al. 2011 | Phase II |
Chemotherapy
- Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
Supportive medications
- No routine growth factors, antibiotic, or antiviral prophylaxis was given
21-day cycle for up to 6 cycles
Regimen #2
Study | Evidence |
Troch et al. 2009 | Phase II |
- Bortezomib (Velcade) 1.5 mg/m2 IV bolus once per day on days 1, 4, 8, 11
Supportive medications
- 5-HT3 antagonist IV immediately before Bortezomib (Velcade)
- 500 mL NS after Bortezomib (Velcade)
21-day cycle for up to 8 cycles
References
- Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. link to original article contains verified protocol PubMed
- Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group (IELSG). Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011 Mar;22(3):689-95. link to original article contains verified protocol PubMed
BR
back to top |
BR: Bendamustine, Rituximab
Regimen
Study | Evidence |
Rummel et al. 2005 | Phase II, <20 patients in this subgroup |
Chemotherapy
Note: the bendamustine infusion instructions are for the Treanda formulation, which was discontinued on 3/31/2016.
- Rituximab (Rituxan) as follows:
- One week prior to start of cycle 1: 375 mg/m2 IV once
- Cycles 1 to 4: 375 mg/m2 IV once on day 1
- 4 weeks after cycle 4: 375 mg/m2 IV once
- Bendamustine 90 mg/m2 IV over 30 minutes once per day on days 2 & 3
28-day cycle for 4 cycles
References
- Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005 May 20;23(15):3383-9. link to original article contains verified protocol PubMed
Cladribine & Rituximab
back to top |
Regimen
Study | Evidence |
Troch et al. 2012 | Phase II, <20 patients reported |
Chemotherapy
- Cladribine (Leustatin) 0.1 mg/kg SC once per day on days 1 to 4
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO prior to Rituximab (Rituxan)
- Antihistamine IV prior to Rituximab (Rituxan)
- Either Ondansetron (Zofran) or Tropisetron (Navoban) IV immediately before Cladribine (Leustatin)
21-day cycle for up to 6 cycles
References
- Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. link to original article contains verified protocol PubMed
Clarithromycin (Biaxin)
back to top |
Regimen
Study | Evidence |
Ferreri et al. 2015 (HD-K) | Phase II |
Antibiotic therapy
- Clarithromycin (Biaxin) 2 g PO once per day on days 1 to 14
21-day cycle for 4 cycles
References
- Ferreri AJ, Sassone M, Kiesewetter B, Govi S, Scarfò L, Donadoni G, Raderer M. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015 Aug;26(8):1760-5. Epub 2015 May 1. link to original article contains verified protocol PubMed
Doxycycline
back to top |
Regimen
Study | Evidence |
Ferreri et al. 2006 | Phase II, <20 patients in this subgroup |
This treatment was intended for patients with ocular adnexal marginal zone lymphoma (OAMZL), given the association with Chlamydia psittaci.
Antibiotic therapy
- Doxycycline 100 mg PO BID
3-week course
References
- Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. link to original article contains verified protocol PubMed
Idelalisib (Zydelig)
back to top |
On 3/21/2016 Gilead announced that they were stopping seven clinical trials of idelalisib in patients with CLL, SLL, and iNHL due to excess deaths and increased rates of SAEs. A REMS program has also been announced.
Regimen,
Study | Evidence |
Gopal et al. 2014 (DELTA) | Phase II, <20 patients in this subgroup |
Chemotherapy
- Idelalisib (Zydelig) 150 mg PO BID
Continued until progression, death, or unacceptable toxicity
References
- Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. N Engl J Med. 2014 Jan 22. link to original article contains verified protocol PubMed
- Update: Abstract: Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, PhD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD and Gilles Andre Salles, MD, PhD. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). ASH Annual Meeting 2014, Abstract 1708 link to abstract
Lenalidomide (Revlimid)
back to top |
Regimen
Study | Evidence |
Kiesewetter et al. 2012 | Phase II, <20 patients reported |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Supportive medications
- Aspirin 100 mg PO once per day
28-day cycle for up to 6 cycles
References
- Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. link to orginal article contains verified protocol PubMed
Rituximab (Rituxan)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Conconi et al. 2003 | Phase II | ||
Martinelli et al. 2005 | Phase II | ||
Williams et al. 2016 (RESORT) | Phase III | Maintenance rituximab | Seems to have inferior TTTF |
Treatment in RESORT was preceded by rituximab and is given at time of progression.
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
One course
References
- Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. link to orginal article contains protocol PubMed
- Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. link to original article contains protocol PubMed
- Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. link to original article contains protocol PubMed
Vorinostat (Zolinza)
back to top |
Regimen
Study | Evidence |
Kirschbaum et al. 2011 | Phase II, <20 pts in subgroup |
Chemotherapy
- Vorinostat (Zolinza) 200 mg PO BID on days 1 to 14
21-day cycles until progression or unacceptable toxicity
References
- Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20;29(9):1198-203. Epub 2011 Feb 7. link to original article contains verified protocol PubMed
Response criteria
NCI Sponsored International Working Group Criteria (1999)
- Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. link to original article PubMed